vs
波士顿科学（BSX）与高露洁棕榄（CL）财务数据对比。点击上方公司名可切换其他公司
高露洁棕榄的季度营收约是波士顿科学的1.0倍（$5.2B vs $5.2B），波士顿科学净利率更高（25.7% vs -0.7%，领先26.4%），波士顿科学同比增速更快（11.6% vs 5.8%），过去两年波士顿科学的营收复合增速更高（12.4% vs 1.6%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
高露洁棕榄是总部位于美国纽约市曼哈顿中城公园大道的跨国消费品企业，主营家居清洁、医疗护理、个人护理、宠物护理等品类产品的生产、分销及相关服务，旗下产品行销全球多地，在日用消费领域拥有广泛的市场认可度。
BSX vs CL — 直观对比
营收规模更大
CL
是对方的1.0倍
$5.2B
营收增速更快
BSX
高出5.8%
5.8%
净利率更高
BSX
高出26.4%
-0.7%
两年增速更快
BSX
近两年复合增速
1.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $5.2B |
| 净利润 | $1.3B | $-36.0M |
| 毛利率 | 69.5% | 60.2% |
| 营业利润率 | — | 1.7% |
| 净利率 | 25.7% | -0.7% |
| 营收同比 | 11.6% | 5.8% |
| 净利润同比 | 99.0% | -104.9% |
| 每股收益（稀释后） | $0.90 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXCL
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $5.2B | ||
| Q3 25 | $5.1B | $5.1B | ||
| Q2 25 | $5.1B | $5.1B | ||
| Q1 25 | $4.7B | $4.9B | ||
| Q4 24 | $4.6B | $4.9B | ||
| Q3 24 | $4.2B | $5.0B | ||
| Q2 24 | $4.1B | $5.1B |
净利润BSXCL
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $-36.0M | ||
| Q3 25 | $755.0M | $735.0M | ||
| Q2 25 | $795.0M | $743.0M | ||
| Q1 25 | $672.0M | $690.0M | ||
| Q4 24 | $563.0M | $738.0M | ||
| Q3 24 | $468.0M | $737.0M | ||
| Q2 24 | $322.0M | $731.0M |
毛利率BSXCL
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | 60.2% | ||
| Q3 25 | 69.9% | 59.4% | ||
| Q2 25 | 67.7% | 60.1% | ||
| Q1 25 | 68.8% | 60.8% | ||
| Q4 24 | 67.8% | 60.3% | ||
| Q3 24 | 68.8% | 61.1% | ||
| Q2 24 | 69.2% | 60.6% |
营业利润率BSXCL
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 1.7% | ||
| Q3 25 | 20.7% | 20.6% | ||
| Q2 25 | 16.2% | 21.1% | ||
| Q1 25 | 19.8% | 21.9% | ||
| Q4 24 | 14.8% | 21.5% | ||
| Q3 24 | 17.4% | 21.2% | ||
| Q2 24 | 12.6% | 21.6% |
净利率BSXCL
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | -0.7% | ||
| Q3 25 | 14.9% | 14.3% | ||
| Q2 25 | 15.7% | 14.5% | ||
| Q1 25 | 14.4% | 14.1% | ||
| Q4 24 | 12.3% | 14.9% | ||
| Q3 24 | 11.1% | 14.6% | ||
| Q2 24 | 7.8% | 14.5% |
每股收益（稀释后）BSXCL
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $-0.04 | ||
| Q3 25 | $0.51 | $0.91 | ||
| Q2 25 | $0.53 | $0.91 | ||
| Q1 25 | $0.45 | $0.85 | ||
| Q4 24 | $0.38 | $0.89 | ||
| Q3 24 | $0.32 | $0.90 | ||
| Q2 24 | $0.22 | $0.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.4B |
| 总债务越低越好 | — | $7.8B |
| 股东权益账面价值 | — | $54.0M |
| 总资产 | — | $16.3B |
| 负债/权益比越低杠杆越低 | — | 145.17× |
8季度趋势，按日历期对齐
现金及短期投资BSXCL
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $1.4B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $534.0M | $1.2B | ||
| Q1 25 | $725.0M | $1.1B | ||
| Q4 24 | $414.0M | $1.3B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.9B | $1.1B |
总债务BSXCL
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | $7.8B | ||
| Q3 25 | $11.1B | — | ||
| Q2 25 | $11.1B | — | ||
| Q1 25 | $10.5B | — | ||
| Q4 24 | $9.0B | $7.0B | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $9.0B | — |
股东权益BSXCL
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $54.0M | ||
| Q3 25 | $23.4B | $856.0M | ||
| Q2 25 | $22.4B | $702.0M | ||
| Q1 25 | $22.2B | $363.0M | ||
| Q4 24 | $21.8B | $212.0M | ||
| Q3 24 | $20.7B | $435.0M | ||
| Q2 24 | $20.4B | $123.0M |
总资产BSXCL
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $16.3B | ||
| Q3 25 | $42.7B | $17.5B | ||
| Q2 25 | $41.6B | $17.5B | ||
| Q1 25 | $40.1B | $16.6B | ||
| Q4 24 | $39.4B | $16.0B | ||
| Q3 24 | $38.1B | $16.8B | ||
| Q2 24 | $37.1B | $16.5B |
负债/权益比BSXCL
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | 145.17× | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | 33.04× | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $1.5B |
| 自由现金流经营现金流 - 资本支出 | — | $1.3B |
| 自由现金流率自由现金流/营收 | — | 24.4% |
| 资本支出强度资本支出/营收 | — | 3.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $3.6B |
8季度趋势，按日历期对齐
经营现金流BSXCL
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.3B | $884.0M | ||
| Q1 25 | $541.0M | $600.0M | ||
| Q4 24 | $1.5B | $1.3B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $813.0M | $990.0M |
自由现金流BSXCL
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $1.3B | ||
| Q3 25 | $1.2B | $1.1B | ||
| Q2 25 | $1.1B | $776.0M | ||
| Q1 25 | $354.0M | $476.0M | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $823.0M | $1.0B | ||
| Q2 24 | $658.0M | $873.0M |
自由现金流率BSXCL
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | 24.4% | ||
| Q3 25 | 22.9% | 21.6% | ||
| Q2 25 | 22.3% | 15.2% | ||
| Q1 25 | 7.6% | 9.7% | ||
| Q4 24 | 25.8% | 21.9% | ||
| Q3 24 | 19.6% | 20.5% | ||
| Q2 24 | 16.0% | 17.3% |
资本支出强度BSXCL
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 3.4% | ||
| Q3 25 | 3.6% | 3.0% | ||
| Q2 25 | 3.1% | 2.1% | ||
| Q1 25 | 4.0% | 2.5% | ||
| Q4 24 | 6.1% | 3.7% | ||
| Q3 24 | 4.3% | 2.7% | ||
| Q2 24 | 3.8% | 2.3% |
现金转化率BSXCL
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | — | ||
| Q3 25 | 1.78× | 1.72× | ||
| Q2 25 | 1.62× | 1.19× | ||
| Q1 25 | 0.81× | 0.87× | ||
| Q4 24 | 2.59× | 1.72× | ||
| Q3 24 | 2.14× | 1.58× | ||
| Q2 24 | 2.52× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
CL
| Other | $3.0B | 58% |
| Pet Nutrition | $1.2B | 23% |
| Oral Personal And Home Care | $1.0B | 20% |
